

Aali B and Nejad S. (2002): *Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.* Acta Obstet Gynecol Scand 81(1):25-30.

Abdul Karim R and Assali N. (1961): *Pressor response to angiotensin in pregnant and non pregnant women.* Am J Obstet Gynecol 82:246.

Adair C, Sanchez-Ramos L, Briones D, et al. (1996): *The effect of high dietary n-3 fatty acid supplementation on angiotensin II pressor response in human pregnancy.* Am J Obstet Gynecol 175:688-691.

Ahmed Y, Van Iddeking B, Paul C, et al. (1993): *Retrospective analysis of platelet members and volumes in normal pregnancy and in preeclampsia.* Br J Obstet Gynecol 100:216-221.

Aksoy H, Taysi S, Altinkaynak K, et al. (2003): *antioxidant potential and transferrin, ceruloplasmin, and lipid peroxidation levels in women with preeclampsia.* J Investing Med. 51(5):284-287.

Albrecht J and Tomich P. (1996): *The maternal and neonatal outcome of triplet gestations.* Am J Obstet Gynecol 174: 1551-1556.

Alexander B, Bennett W, Khalil R, et al. (2001): *Preeclampsia: Linking Placental Ischemia with Cardiovascular-Renal Dysfunction.* News Physiol Sci 16:282-286.

American College of Obstetricians and Gynecologists (ACOG). (2002): *Diagnosis and management of preeclampsia and eclampsia.* Committee on Obstetric Practice. ACOG practice bulletin № 33. Int J Obstet Gynecol 77(1):67-75.

Ananth C, Bowes W, Savitz D, et al. (1997): *Relationship between pregnancy-induced hypertension and placenta previa: A population-based study.* Am J Obstet Gynecol 177:997-1004.

Apollon K, Robinson J, Schwartz R, et al. (2000). *Cortical blindness in severe preeclampsia: Computed tomography, magnetic resonance imaging and single-photon emission computed tomography findings.* Obstet Gynecol 95:1017-1019.

Aquilina J, Barnett A, Thomposon O, et al. (1999): *Second-trimester maternal serum inhibin A concentrations as an early marker for preeclampsia.* Am J Obstet Gynecol 181:131-140.

Arborgast B, Leeper S, Merrick R, et al. (1996): *Plasma factors that determine endothelial cell lipid toxicity in vitro correctly identifying women with preeclampsia in early and late gestation.* Hypertens Pregnancy 15:263-291.

Arias F. (1993): *preeclampsia and eclampsia. In practical guide to high risk pregnancy and delivery*, 2nd edition Louis S, Philadelphia: Mosbay Year Book 183-207.

Ascarelli M, Johnson V, Mc Creary et al. (2005): *postpartum preeclampsia management with Furosemide. A randomized clinical trial.* Obstet Gynecol 105:29-33.

Audibert F, Friedman S, Frangieh A, et al. (1996): *Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome.* Am J Obstet Gynecol 175:460-464.

Aune B, Gjesdal K and Oian P. (1999): *Late onset postpartum thrombocytosis in preeclampsia.* Acta Obstet Gynecol Scand 78(10):866-870.

Ayaz T, Akansel G, Hayirlioglu A, et al. (2003): *Ophthalmic artery color Doppler ultrasonography in mild-to-moderate preeclampsia.* Eur J Radiol 46(3):244-249.

Barton J, Sibai B, Whybrew W, et al. (1993): *Urinary endothelin-1: Not a useful marker for preeclampsia.* Am J Obstet Gynecol 168: 599.

Bayhan G, Atamer Y, Atamer A, et al. (2000): *Significance of changes in lipid peroxides and antioxidant enzyme activities in pregnant women with preeclampsia and eclampsia.* Clin Exp Obstet Gynecol 27(2): 142-146.

Belfort M, Grunewald C, Saade G, et al. (1999): *Preeclampsia may cause both overperfusion and underperfusion of the brain: A cerebral perfusion based model.* Acta Obstet Gynecol Scand 78:586-591.

Beneditto C, Marozio L, Neri I, et al. (2000): *Increased L – citrulline /L- arginine plasma ratio in sever preeclampsia.* Obstet Gynecol 96:395.

Benyo D, Adatisa P and Conrad K. (2000): *Levels of inflammatory cytokines in normal term and preeclamptic placentas and their regulation by oxygen.* J Soc Gynecol Investig 7(1):894.

Bilodeau J and Hubel C. (2003): *Current concepts in the use of antioxidants for the treatment of preeclampsia.* J Obstet Gynaecol Can 25:742-750.

Bolte A, Van Geijn H and Dekker G. (2001): *Pathophysiology of preeclampsia and the role of serotonin.* Eur J Obstet Gynecol. Reprod Biol 95(1): 12-21.

Bosio P, Wheeler T, Anthony F, et al. (2001): *Maternal plasma vascular endothelial growth factor concentration in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance.* Am J Obstet Gynecol 184:146-152.

Bouba I, Makrydimas G, Kalaitzidis R, et al. (2003): *Interaction between the polymorphisms of the renin-angiotensin system in preeclampsia.* Eur J Obstet Gynecol Reported Biol 10; 110(1):8-11.

Branch D, Porter T, Rittenhouse L, et al. (2001): *Antiphospholipid antibodies in women at risk for preeclampsia.* Am J Obstet Gynecol 184:825-834.

Brockelsby J, Anthony F, Johnson I, et al. (2000): *The effects of vascular endothelial growth factor on endothelial cells: a potential role in preeclampsia.* Am J Obstet Gynecol 182 (1Pt1):176-183.

Brosens I, Robertson W and Dixon H. (1972): *The role of the spiral arteries in the pathogenesis of preeclampsia.* Obstet Gynecol Annu 1:177-191.

Brown C, Cunningham F and Pritchard J. (1987): *Convulsions in hypertension, proteinuria primiparas more than 24 hours after delivery: Eclampsia or some other causes.* J report Med 32-499.

Brown M, Hague W, Higgins J, et al. (2000): *The detection, investigation and management of hypertension in pregnancy: full consensus statement.* Aust N Z J Obstet Gynaecol 40:139–55.

Caritis S, Bibai B, Hauth J, et al. (1998): *Low-Dose Aspirin to prevent preeclampsia in women at high risk.* NEJM Sponsored 338:701-705.

Casanueva E and Viteri F. (2003): *Iron and oxidative stress in pregnancy.* J Nutr 133:1700s-1708s.

Chambers J, Fusi L, Malik I, et al. (2001): *Association of maternal endothelial dysfunction with preeclampsia.* JAMA 28; 285 (12):1607-1612.

Chang J, Roman C and Heymann M. (1992): *Effect of endothelium-derived relaxing factor inhibition on the umbilical-placental circulation in fetal lambs in utero.* Am J Obstet Gynecol 166:727-730.

Chappell L and Bewley S. (1998): *Preeclamptic toxemia: The role of uterine artery Doppler.* Br J Obstet Gynecol 105:379-382.

Chappell L, Seed P, Briley A, et al. (1999): *Effect of antioxidants on the occurrence of preeclampsia in women at increased risk.* Lancet 354:810.

Chuan F, Charles B, Boyle R, et al. (2001): *Population pharmacokinetics of magnesium in preeclampsia.* Am J Obstet Gynecol 185:593-599.

Clark B, Halvorson L, Sachs B, et al. (1992): *Plasma endothelin level in preeclampsia. Elevation and correlation with uric acid levels and renal impairment.* Am J Obstet Gynecol 166:962-966.

Clausen T, Slott M, Solvoll K, et al.(2001): *High intake of energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of preeclampsia.* Am J Obstet Gynecol 185:451-458.

Conrad K and Vernier K. (1989): *Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats.* Am J Physiol Regulatory Integrative Comp Physiol 257:R847-R853.

Conrad K, Kerchner L and Mosher M. (1999): *Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet.* Am J Physiol Renal Physiol 277:F48-F57.

Conradt A, Weidinger H and Algayer H. (1984): *On the role of magnesium in fetal hypertrophy, pregnancy-induced hypertension and preeclampsia.* Mag Bull 6:68-73.

Coomarasamy A, Honest H, Papaioannou S, et al. (2003): *Aspirin for prevention of preeclampsia in women with historical risk factors.* Obstet Gynecol 101(6):1319-1332.

Coomarasamy A, Papaioannou S, Gee H, et al. (2001): *Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis (1).* Obstet Gynecol 98:861-866.

Cotter A, Molloy A, Scott J, et al. (2001): *Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia.* Am J Obstet Gynecol 185 (4): 781-785.

Cunningham F and Leveno K. (1988): *Management of pregnancy-induced hypertension:* In Hand book of Hypertension. X: Hypertension in Pregnancy. Rubin PC, Amsterdam, Elsevier Science 290.

Cunningham F and Twickler D. (2000): *Cerebral edema complicating eclampsia.* Am J Obstet Gynecol 182:94-100.

Cunningham F, Gant N, Leveno K, et al. (2001): *Hypertensive disorders in pregnancy:* In Williams Obstetrics, 21th ed, United States of America: McGraw-Hill, Appelton & Lange II: 567-618.

Cunningham F, MacDonald P, Leveno KJ, et al. (1993): *Hypertensive disorders in pregnancy:* In Williams obstetrics, 19th ed. 1 San Mateo California: Norwalk, connectient. Appleton & Lange 763-817.

De Boer K, Buller H, ten Cate J, et al. (1991): *Coagulation studies in the syndrome of haemolysis elevated liver enzymes, and low platelets.* Br J Obstet Gynecol 98:42-47.

De Wolf F, Brosens I, Renaer M. (1980): *Fetal growth retardation and the maternal arterial supply of the human placenta in the absence of sustained hypertension.* Br J Obstet Gynecol 87:678-685.

Deborah M. (2000): *Role of nutrition in the prevention of Toxemia.* Am J Clin Nutr 72(1):298s-300s.

Dekker G, Kraayenbrink A, Zeeman G, et al. (1991): *Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia.* Eur J Obstet Gynecol Reprod Biol 40:215-220.

Dekker G, Makovitz J and Wallenburg H. (1990): *Prediction of pregnancy-induced hypertensive disorders by angiotensin II sensitivity and supine pressor test.* Br J Obstet Gynecol 97:817-822.

Diedrich F, Renner A, Rath W, et al. (2001): *Lipid hydroperoxides and free radical scavenging enzyme activities in preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: No evidence for circulating primary products of lipid peroxidation.* Am J Obstet Gynecol 185:166-172.

DiFederico E, Genbacev O and Fisher S. (1999): *Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall.* Am J Pathol 155:293-301.

Dommissie J. (1990): *Phenytoin sodium and magnesium sulfate in the management of eclampsia.* Br J Obstet Gynecol 97:104-108.

Duley L, Henderson-Smart D, Knight M, et al. (2004): *Antiplatelet agents for preventing preeclampsia and its complications.* Cochrane Database Syst Rev (1):CD004659.

Duley, L, Henderson-Smart D, Knight M, et al. (2001): *Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review.* Br Med J 322:329-333.

Farid A, Ali M, El Bambi M, et al. (1998): *The effect of honey bee stings on preeclampsia, 6th world congress of Gynecological Endocrinology.* Crans Montana Switzerland (3):18-20.

Fitzgerald D, Rocki W, Murray R, et al. (1990): *Thromboxane A₂ synthesis in pregnancy-induced hypertension.* Lancet 335:751-754.

Friedman S and Lindheimer M. (1999): *Prediction and differential diagnosis.* In Hypertensive disorders in pregnancy. 2nd edition, Lindheimer M, Roberts J and Cunningham G (eds). Stanmford CT, Appleton and Lange 20:45-52.

Fugate S and Meyer B. (2001): *Eclampsia.* Med J 25; 2(7).

Gant N, Chand S, Wallery P, et al. (1973): *A study of angiotensin II pressor response through primigravida pregnancy.* J Clinical invests 52:2682-2689.

Granger J, Alexander B, Llinas M, et al. (2001): *Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction.* Hypertension 38 (3pt2):718-722.

Granger J, Alexander B, Llinas M, et al. (2002): *Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction.* Microcirculation 9(3):147-160.

Gregory D, Pelak V and Bennett J. (2003): *Diffusion-weighted magnetic resonance imaging and the evaluation of cortical blindness in preeclampsia.* Surv Ophthalmol 48(6):647-650.

Gupta S, Agarmal A and Sharma R. (2005): *The role of placental oxidative stress and lipid peroxidation in preeclampsia.* Obstet Gynecol Surv 60(12):807-816.

Hachim K, Badahi K, Benghanem M, et al. (2001): *Obstetrical acute renal failure, Experience of the nephrology department, Central University Hospital in Rochd, Casablanca.* Nephrologic 22:29-31.

Hall D, Odendaal H, Steyn D, et al. (2002): *Urinary protein excretion and expectant management of early onset, severe preeclampsia.* Int J Obstet Gynecol 77:210-216.

Halligan A, Bonnar J, Sheppard B, et al. (1994): *Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and preeclampsia.* Br J Obstet Gynecol 101:488-493.

Haram K, Softeland E, Hervig T, et al. (2003): *Thrombocytopaenia in pregnancy.* Tidsskr Nor Laegeforen. 123:2250-2252.

Harnett M, Datta S and Bhavani-Shankar K. (2001): *The effect of magnesium on coagulation in parturients with preeclampsia.* Anesth Analg 92(5):1257-1260.

Hayman R, Warren A, Brockelsby J, et al. (2000): *Plasma from women of Preeclampsia induces an in vitro alternation in endothelium-dependant behaviors of myometrial resistant arteries.* Br J Obstet Gynecol 107:108-112.

Hayman R, Warren A, Johnson I, et al. (2001): *The preliminary characterization of a vasoactive circulating factor(s) in preeclampsia.* Am J Obstet Gynecol 184:1196-1203.

Henriksen T. (2000): *The role of lipid oxidation and oxidative lipid derivatives in the development of preeclampsia.* Semin Perinatol 24(1):29-32.

Hermida R, Ayala D and Iglesias M. (2003): *Administration Time-Dependent Influence Blood Pressure in Pregnant Women.* Hypertension 41:651-667.

Hofmeyr G, Roodt A, Atallah A, et al. (2003): *Calcium supplementation to prevent Preeclampsia -a systematic review* SAfr Med J 93(3):224-228.

Holmes V and Mc Cance D. (2005): *Could antioxidant supplementation prevent preeclampsia?* Proc Nutr Soc 64(4):491-501.

Holzgreve W, Li J, Steinborn A, et al. (2001): *Elevation in erythroblast count in maternal blood before the onset of preeclampsia.* Am J Obstet Gynecol 184:165-168.

Homuth V, Dechend R and Luft F. (2003): *When should pregnant women with an elevated blood pressure be treated?* Nephrol Dial Transplant 18:1456–1457.

Hsu C, Chan D, Iriye B, et al. (1994): *Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia.* Am J Obstet Gynecol 170:1135–1138.

Hubel C, Kagan V, Kisin E, et al. (1997): *Increased ascorbate radical formation and ascorbate depletion in plasma from women with preeclampsia: implication for oxidative stress.* Free Radic Biol Med 23:597-601.

Hubel C, McLaughlin M, Evans R, et al. (1996): *Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours postpartum.* Am J Obstet Gynecol 174:975-980.

Hubel C, Roberts J, Taylor R, et al. (1989): *Lipid peroxidation in pregnancy new prospective on preeclampsia.* Am J Obstet Gynecol 158:892-898.

Hubel C. (1999): *Oxidative Stress in the Pathogenesis of preeclampsia.* Proc Soc Exp Biol Med 222:222-235.

Hunter A, Aitkenhead M, Caldwell C, et al. (2000): *Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy.* Hypertension 36:965-980.

Hunter C and Howard W. (1960): *A pressor substance (hysterotonin) occurring in toxemia.* Am J Obstet Gynecol 79: 838-846.

Hunter C, Howard W and McCormick C. (1961): *Amelioration of the hypertension of toxemia by postpartum curettage.* Am J Obstet Gynecol 81:884-889.

Hutton J, James D and Sirrat G. (1992): *Management of severe preeclampsia and eclampsia by UK consultants.* Br J Obstet Gynecol 99:554.

Ibrahim M, Wagdy A, El-Nashar A, et al. (1997): *Immediate postpartum curettage in cases of severe preeclampsia.* Tanta Medical Journal 25(1):1368-1374.

Innes K and Wimsatt J. (1999): *Pregnancy-induced hypertension and insulin resistance: evidence for a connection.* Act Obstet Gynecol Scand 78:263-284.

Irion O, Masse J, Forest J, et al. (1998): *Prediction of preeclampsia; low birthweight for gestation and prematurity by*

uterine artery blood flow velocity waveform analysis in low risk nulliparous women. Br J Obstet Gynecol 105:422-426.

Ito T, Sakai T, Inagawa S, et al. (1995): *MR angiography of cerebral vasospasm in preeclampsia.* Am J Neuroradiol 2; 16(6): 1344-1346.

James P and Nelson-Piercy C. (2004): *Management of hypertension before, during and after pregnancy.* Heart 90:1499-1504.

Judith H. (1997): *Aggressive management of HELLP syndrome and eclampsia.* AACN Clinical Issues vol. 8 Number 4.

Kanayama N. (2003): *Trophoblastic injury: new Etiological and pathological concept of preeclampsia.* Croat Med J 44 (2): 148-156.

Kathula S, Bolla S, and Magann E. (2002): *HELLP syndrome leading to diagnosis of pregnancy.* South med J 95:934-935.

Khalil R and Granger J. (2002): *Vascular mechanisms of increased arterial pressure in preeclampsia.* Physiol Regul Integr Comp Physiol 283(Issue 1):R29-R45.

Khalil R, Crews J, Novak J, et al. (1998): *Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats.* Hypertension 31:1065-1069.

Kilby M, Broughton F and Symmonds E. (1994): *Pharmacological prophylaxis in pregnancy induced hypertension.* In Progress in Obstet Gynecol. Studd J (ed.) Robert Stevenson House, United Kingdom 12:53-73.

Knuist M, Bonsel G, Zondervan H, et al. (1998): *Low sodium diet and pregnancy-induced hypertension: A multicentre randomized controlled trial.* Br J Obstet Gynecol 15: 209-212.

Lachmeijer A, Arngrimsson R, Bastiaons E, et al. (2001): *Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia.* Am J Obstet Gynecol 184:394-402.

Ladipo O. (2000): *Nutrition in pregnancy: mineral and vitamin supplements.* Am J of Clinical Nutrition 72(1):280s-290s.

Laivuori H, Lahermo P, Ollikainen V, et al. (2003): *Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families.* Am J Hum Genet 72:168-177.

Landau R and Irion O. (2005): Recent data on the physiopathology of preeclampsia and recommendations for treatment. Rev Med Suisse 26; 1(4):290,292-295.

Lapinsky S and Mehta S. (2002): *Activated protein C for preeclampsia: tailoring the disease to the therapy.* Crit Care Med 30:1929-1930.

Lazebnik N, Kuhnert B, Kuhnert B, et al. (1988): *Zink status, pregnancy complications and labor abnormalities.* Am J Obstet Gynecol 158:161.

Lee C, Hsu T, Ou C, et al. (1999): *Retinal detachment in postpartum preeclampsia and eclampsia: report of two cases.* Changeng Yi Xue Za Zhi 22(3):520-524.

Lee E. (1992): *Statistical methods for survival data analysis* 2nd ed. John Wiley and sons. Inc. New York.

Lim K, Friedman S, Ecker J, et al. (1998): *The clinical utility of serum uric acid measurements in hypertensive disease of pregnancy.* Am J Obstet Gynecol 178:1067.

Liu Q, He J, Dong My, et al. (2005): Clinical features and prognosis of early-onset preeclampsia. Zhejiang Da Xue Xue Bao Yi Xue Ban 34(6):506-509.

Livingston J, Haddad B, Gorski L, et al. (2001): *Placental growth factor is not an early marker for the development of severe preeclampsia.* Am J Obstet Gynecol 184(6):1218-1220.

Lopes-Jaramillo P, Delgado F, Jacome P, et al. (1997): *Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers.* Obstet Gynecol 90:162-167.

Lorentzen B and Henriksen T. (1998): *Plasma lipids and vascular dysfunction in preeclampsia.* Semin Reprod Endocrinol 16:33-39.

Louden K, Brouton P and Heptinsall S. (1994): *Neonatal platelet reactivity and serum thromboxane A₂ production in whole blood: The effect of maternal low dose aspirin.* Br J Obstet Gynecol 101:203-208.

Lyall F, Greer I, Boswell F, et al. (1997): *Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia.* Br J Obstet Gynaecol 104:223-228.

Mabie W, Gonzalez A, Sibai B, et al. (1987): *A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy.* Obstet Gynecol 70:328.

Madazli R, Budak E, Calay Z, et al. (2000): *Correlation between placental bed biopsy findings, vascular cell adhesion molecule and fibronectin levels in preeclampsia.* Br J Obstet Gynecol 107:514.

Magann E, Bass J, Chauhan S, et al. (1994): *Accelerated recovery from severe preeclampsia: Uterine curettage versus nifedipine.* J Soc Gynecol Investig 1(3):210-214.

Magann E, Martin J, Isaacs J, et al. (1993): *Immediate postpartum curettage: accelerated recovery from severe preeclampsia.* Obstet Gynecol 81(4):502-506.

Magann E, Martin J, Isaacs J, et al. (1995): *Immediate postpartum curettage accelerated recovery from severe preeclampsia.* Obstet Gynecol Am J 22:337- 356.

Magee L, Ornstein M and von Dadelszen P. (1999): *Management of hypertension in pregnancy.* BMJ 318:1332–1336.

Many A, Hubel C, Fisher S, et al. (2000): *Invasive Cytotrophoblasts Manifest Evidence of Oxidative Stress in Preeclampsia.* Am J of Pathology 156(1):321-331.

Maynard S, Min J, Merchan J, et al. (2003): *Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.* J Clin Invest 111(5):649-58.

Mellembakken J, Aukrust P, Hestdal K, et al. (2001): *Chemokines and leukocyte activation in the fetal circulation during preeclampsia.* Hypertension 38:394–398.

Mellembakken J, Aukrust P, Mette K, et al. (2002): *Activation of leukocytes During the Uteroplacental passage in Preeclampsia.* Hypertension 39:155-168.

Mikhail M, Anyaegbunam A, Garlinkel D, et al. (1994): *Preeclampsia and antioxidant nutrients: Decreased plasma levels of reduced ascorbic acid, α -tocopherol, and beta carotene in women with preeclampsia.* Am J Obstet Gynecol 170:137-141.

Millar J, Campbell S, Albano J, et al. (1996): *Early prediction of preeclampsia by measurement of kallikrein and creatinine on a random urine sample.* Br J Obstet Gynecol 103:42-49.

Morris N, Eaton B and Dekker G. (1996): *Nitric oxide, the endothelium, pregnancy and pre-eclampsia.* Br J Obstet Gynaecol 103:4-15.

Mutlu-Turkoghu U, Aykac-Toker G, Ibrahimoglu L, et al. (1999): *Plasma nitric oxide metabolites and lipid peroxide levels in preeclamptic pregnant women before and after delivery.* Gynecol Obstet Invest 48:247-250.

Myatt L. (1986): *Eicosanoides and blood pressure regulation .In hypertension and Pregnancy, Proceeding of the 16 study group for the RCOG, USA: Prenatology press 3:167-187.*

Nelson S, Steinsland O, Wang Y, et al. (2000): *Increased nitric oxide synthase activity and expression in the human uterine artery during pregnancy.* Circ Res 87:406-411.

Newman M, Robichaux A, Stedman C, et al. (2003): *Perinatal outcomes in preeclampsia that is complicated by massive proteinuria.* Am J Obstet Gynecol 188(1):264-268.

Nie H, Hadlai H, Jenkins J, et al. (1979): *Statistical package for the social sciences (SPSS).* New York, McGraw-Hill.

North R, Ferrier C, Gamble G, et al, (1995): *Prevention of preeclampsia with heparin and antiplatelet drugs with renal disease in women.* Aust NIJ Obstet Gynecol 35:357-362.

Norwitz E, Hsu C and Repke J. (2002): *Acute Complications of Preeclampsia.* Clin Obstet Gynecol 45 (2):308-329.

Norwitz E, Robinson J and Repke J. (1999): *Prevention of preeclampsia: Is It Possible?* Clin Obstet Gynecol 42 (3):436-454.

Odegard R, Vattne L, Nilsen S, et al. (2000): *Risk factors and clinical manifestations of preeclampsia.* BJOG 107: 1410-1416.

Ohno Y, Kawai M, Wakahara Y, et al. (1999): *Ophthalmic artery velocimetry in normotensive and preeclamptic women with or without photophobia.* Obstet Gynecol 94:361.

Olsen S, Secher N, Tabor A, et al. (2000): *Randomized clinical trials of fish oil supplementation in high risk pregnancies.* Br J Obstet Gynecol 107:382.

Omu A, Al-Azemi M, Al-Qattan F, et al. (2004): *Connection between human leucocyte antigens D region and T helper cytokines in preeclampsia.* Arch Obstet Gynecol 269(2): 79-84.

Oney T and Kaulhausen H. (1982): *The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy.* Am J Obstet Gynecol 142:17-20.

Osmanagaoglu M, Topcuoglu K, Ozeren M, et al. (2005): *Coagulation inhibitors in preeclamptic pregnant women.* Arch Gynecol Obstet 271(3):227-230.

Otani S, Usuki S, Saitoh T, et al. (1991): *Comparison of endothelin-1 concentrations in normal and complicated pregnancies.* J Cardiovasc Pharmacol 17:S308.

Pabinger I, Grafenhofer H, Kaider A, et al. (2001): *Arteriosclerosis Thrombosis, and Vascular Biology.* American Heart Association, Inc 21:874.

Padden M. (1999): *HELLP Sundrome: Recognition and Perinatal Management.* Am Fam Physician 60:829-839.

Palan P, Mikhail M and Romney S. (2001): *Placental and serum levels of carotenoids in preeclampsia.* Obstet Gynecol 98(3):459-462.

Pickles C, Brinkman C, Stainer K, et al. (1989): *Changes in peripheral venous tone before the onset of hypertension in women with gestational hypertension.* Am J Obstet Gynecol 160: 678-680.

Pipkin F. (1995): *Fortnightly Review: The hypertensive disorders of pregnancy.* BMJ (2) 311:609-613.

Pipkin F. (2001): *Risk factors for preeclampsia.* New Engl J Med 344:925-926.

Redman C, Sacks G, Sargent I, et al. (1999): *Preeclampsia: An excessive maternal inflammatory response to pregnancy.* Am J Obstet Gynecol 180:499-506.

Regan C, Levine R, Baird D, et al. (2001): *No evidence for lipid peroxidation in severe preeclampsia.* Am J Obstet Gynecol 185:572-578.

Reif M. (2003): *Preeclampsia. Why diagnosis can be difficult.* Women's Health in Primary Care 6(5):235-243.

Roberson S and Howel M. (1994): *Preeclampsia.* Br J Obstet Gynecol 101:639.

Roberts J, Balk J, Bodnar L, et al. (2003): *Supplement: Nutrition as a Preventive Strategy against adverse pregnancy outcomes. Nutrient Involvement in preeclampsia.* The American Society for Nutritional Sciences J. Nutr. 133:1684s-1692s.

Robson S. (1996): *Magnesium sulphate: The timing of reckoning.* Br J Obstet Gynecol 103:99.

Rodgers G, Taylor R and Roberts J. (1988): *Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells.* Am J Obstet Gynecol 159:908-914.

Rogers B, Bloom S and Leveno K. (1999): *Atherosclerosis revisited: Current concepts on the pathophysiology of implantation site disorders.* Obstet Gynecol Surv 54:189.

Romero R. (2003): *Intrauterine infection, premature birth and the fetal inflammatory response syndrome.* J Nutr 133: 1668S-1673S.

Rowland B, Vermillion S and Rowdebush W. (2000): *Elevated circulating concentrations of platelet activating factor in preeclampsia.* Am J Obstet Gynecol 183(4):930-932.

Rush D. (2000): *Nutrition and maternal mortality in the developing world.* Am J Clin Nutr 72 (suppl):212S-240S.

Sakura M, Nakabayashi M, Takeda Y, et al. (1998): *Elevated fetal fibronectin in midtrimester amniotic fluid is involved with the onset of preeclampsia.* J Obstet Gynecol Res 24(1):73-76.

Salvig J, Olsen S and Secher N. (1996): *Effects of fish oil supplementation in late pregnancy on blood pressure: A randomized controlled trial.* Br J Obstet Gynecol 103:529-533.

Sanchez-Ramos L, Jones D and Cullen M. (1991): *Urinary calcium as an early marker for preeclampsia.* Obstet Gynecol 77:685.

Schelenzing G, Maurer S, Goppelt M, et al. (2000): *Postpartum Curettage with HELLP syndrome.* Eur J obstet Gynecol Reprod Biol 91(1): 25-28 (ISSN: 0301-2115).

Schiff E, Friedman S, Stampfer M, et al. (1996): *Dietary consumption and plasma concentrations of vitamin E in pregnancies complicated by preeclampsia.* Am J Obstet Gynecol 175:1024.

Schneider H. (1994): *Liver Pathology within the scope of HELLP syndrome.* Arch Obstet Gynecol 255:245.

Seki D. (1995): *The role of thromboxane A2 synthetase inhibitors in prevention of preeclampsia.* Br J Obstet Gynecol 132:456-460.

Seligman S, Buyon J, Clancy R, et al. (1994): *The role of nitric oxide in the pathogenesis of preeclampsia.* Am J Obstet Gynecol 171:944-948.

Shamash A, Elsnosy E, Makhoul A, et al. (2000): *Maternal and fetal serum nitric oxide (NO) concentrations in normal pregnancy, pre-eclampsia and eclampsia.* Int J Gynaecol Obstet 68:207-214.

Sibai B, Mabie B, Harvey C, et al. (1987): *Pulmonary edema in severe preeclampsia-eclampsia: Analysis of thirty-seven consecutive cases.* Am J Obstet Gynecol 156:1174.

Sibai B, Ramanathan J and Coleman P. (1991): *Anesthetic modification of hemodynamic and neuroendocrine stress responses to cesarean delivery in women with severe preeclampsia.* Anesthesia & Analgesia 73:772-779.

Sibai B, Villar M and Broy E. (1989): *Magnesium supplementation during pregnancy: A double blind randomized controlled clinical trial.* Am J Obstet Gynecol 161:115-119.

Sibai B. (1992): *Hypertension in pregnancy.* Obstet Gynecol Clin North Am 19:15-32.

Sibai B. (2003): *Diagnosis and management of gestational hypertension and preeclampsia.* Obstet Gynecol 102(1):181-192.

Simmons L, Hennessy A, Gillin A, et al. (2000): *Uteroplacental blood flow and placental vascular endothelial growth factor in normotensive and preeclamptic pregnancy.* Br J Obstet Gynecol 107:678.

Smith R and Baker P. (2005): *Risk factors, prevention and treatment of hypertension in pregnancy.* Minerva Gynecol 57(4):379-388.

Sorensen J, Olsen S, Pedersen A, et al. (1993): *Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production.* Am J Obstet Gynecol 168:915-922.

Soutoul J and Berger C. (1969): *Place of uterine curettage in postpartum eclampsia.* Bull Fed Soc Obstet Gynecol 21(1):54-59.

Staff A, Ranheim T, Khovry J, et al. (1999): *Increased contents of phospholipids, cholesterol, and lipid peroxides in decidua basalis in women with preeclampsia.* Am J Obstet Gynecol 180(3Pt1):587-592.

Stark J. (1995): *Preeclampsia and cytokine induced oxidative stress.* Br J Obstet Gynecol 100:105-109.

Steegers E, Eskes T, Jongsma H, et al. (1991): *Dietary sodium restriction during pregnancy: A historical review.* Eur J Obstet Gynecol Reprod Biol 40:83-90.

Su Y, Lee C, Cheng W, et al. (2001): *Decreased maternal serum placenta growth factor in early second trimester and preeclampsia.* Obstet Gynecol 97(6):898-904.

Subtil D, Goeusse P, Puech F, et al. (2003): *Aspirin (100 mg) used for prevention of Preeclampsia in nulliparous women.* Br J Obstet Gynecol 110(5):475-484.

Taylor R, Varma M, Teng N, et al. (1990): *Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies.* J Clin Endocrinol Metab 71: 1675-1677.

Thiele I, Niezen-Koning K, Gennip A, et al. (2004): *Increased plasma carnitine concentration in preeclampsia.* Obstet Gynecol 103:876-880.

Treloar S, Cooper D, Brennecke S, et al. (2001): *An Australian twin study of the genetic basis of preeclampsia and eclampsia.* Am J Obstet Gynecol 184:374-381.

Trudinger B and Cook C. (1990): *Doppler umbilical and uterine flow waveforms in severe pregnancy hypertension.* Br J Obstet Gynecol 97:142.

Tyurin V, Liu S, Tyurina Y, et al. (2001): *Elevated levels of S-nitrosoalbumin in preeclampsia plasma.* Circ Res 88: 1210-1215.

Uotila J, Tuinaala R, Aarnis T, et al. (1993): *Peroxidation and antioxidant function in hypertensive complications of pregnancy.* Br J Obstet Gynecol 100(3):27-36.

Uzan S, Beaufils M, Breart G, et al. (1991): *Prevention of fetal growth retardation with low dose aspirin. Find of the EPREDA trial.* Lancet I, 337:1427-1231.

Van F, Spitz b, Vermynen j, et al. (1985): *Priliminary observation on the treatment of pregnancy induced hypertension with thromboxane synthetase inhibitors.* Am J Obstet Gynecol 148:216-218.

Vickers M, Ford I, Morrison R, et al. (2003): *Markers of endothelial activation and atherothrombosis in women with history of preeclampsia or gestational hypertension.* Thromb Haemost. 90(6):1192-1197.

Von D, Ornstein M, Bull S, et al. (2000): *Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis.* Lancet 355:87–92.

von Dadelszen P, Menzies J and Magee L. (2005): The complications of hypertension in pregnancy. Minerva Med 96(4):287-302.

Walsh S. (2004): *Eicosanoids in preeclampsia.* Prostaglandins Leukot Essent Fatty Acids 70(2):223-232.

Wang Y, Walsh S and Kay H. (1992): *Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preeclampsia.* Am J Obstet Gynecol 167: 946-949.

Wanger L. (2004): Diagnosis and management of preeclampsia. Am Fam Physican 70:2317-2324.

Weerasekera D and Peiris H. (2003): *The significance of serum uric acid, creatinine and urinary microprotein levels in predicting Preeclampsia.* J Obstet Gynaecol 23:17-19.

Williams K and Wilson S. (1999): *Persistence of cerebral hemodynamic changes in patients with eclampsia: a report of three cases.* Am J Obstet Gynecol 181: 1162.

Yoneyama Y, Sawa R, Suzuki S, et al. (2002): *Relationship between plasma malondialdehyde levels and adenosine deaminase activities in preeclampsia.* Clin Chim Acta 322(1-2):169-173.

Zhang J, Christianson R and Torfs C. (2004): *Fetal trisomy 21 and maternal preeclampsia.* Epidemiology 15:195-201.

Zhong X, Holzgreve W and Hahn S. (2002): *The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia.* Hypertention in pregnancy 21(1):77-83.

Zhong X, Laivuori H, Livingston J, et al. (2001): *Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia.* Am J Obstet Gynecol 184:414-419.